<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TRIMETHOBENZAMIDE HYDROCHLORIDE</span><br/>(trye-meth-oh-ben'za-mide)<br/><span class="topboxtradename">Arrestin, </span><span class="topboxtradename">Ticon, </span><span class="topboxtradename">Tigan, </span><span class="topboxtradename">T-Gen<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span><br/><b>Prototype: </b>Prochlorperazine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>100 mg, 250 mg, 300 mg capsules; 100 mg, 200 mg suppositories; 100 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Structurally related to ethanolamine antihistamines, but in therapeutic doses antihistamine activity is weak. Sedative and
         antiemetic actions; less effective than phenothiazine antiemetics but produces fewer adverse effects. Must be used with other
         agents when vomiting is severe. Primary locus of action is thought to be the chemoreceptor trigger zone (CTZ) in medulla.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Less effective than phenothiazine antiemetics but produces fewer adverse effects.</p>
<h1><a name="uses">Uses</a></h1>
<p>Control of nausea and vomiting.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Uncomplicated vomiting in viral illness; parenteral use in children; rectal administration in prematures and newborns; known
         sensitivity to benzocaine (in suppository) or to similar local anesthetics. Safety during pregnancy (category C) or lactation
         is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients who have recently received other centrally acting drugs; in presence of high fever, dehydration, electrolyte imbalance.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Nausea and Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250300 mg t.i.d. or q.i.d. <span class="rdroute">Rectal/IM</span> 200 mg t.i.d. or q.i.d.<br/><span class="rdage">Child:</span> <span class="rdroute">PO/Rectal</span> <i>1545 kg,</i> 100200 mg t.i.d. or q.i.d. <span class="rdroute">Rectal</span> <i> 100 mg t.i.d. or q.i.d.<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Empty capsule and give with water or mix with food if patient cannot swallow capsule.</li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Give IM deep into upper outer quadrant of buttock.</li>
<li>Minimize possibility of irritation and pain by avoiding escape of solution along needle track. Use Z-track technique. Rotate
            injection sites.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Hypersensitivity reactions (including allergic skin eruptions), muscle cramps, pain, stinging, burning, redness, irritation
      at IM site; local irritation following rectal administration. <span class="typehead">CNS:</span> Pseudoparkinsonism. <span class="typehead">CV:</span> Hypotension. <span class="typehead">GI:</span> Diarrhea, exaggeration of nausea, acute hepatitis, jaundice. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Alcohol and other <span class="classification">cns depressants</span> add to depressant activity; <span class="classification">belladonna alkaloids</span> may intensify anticholinergic effects; <span class="classification">phenothiazines</span> may precipitate extrapyramidal syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 1040 min PO; 15 min IM. <span class="typehead">Duration:</span> 34 h PO; 23 h IM. <span class="typehead">Elimination:</span> 3050% of dose excreted unchanged in urine within 4872 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BP. Hypotension may occur particularly in surgical patients receiving drug parenterally.</li>
<li>Report promptly and stop drug therapy if an acute febrile illness accompanies or begins during therapy.</li>
<li>Antiemetic effect of drug may obscure diagnoses of GI or other pathologic conditions or signs of toxicity from other drugs.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly to physician onset of rash or other signs of hypersensitivity (see Appendix F). Discontinue drug immediately.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not drink alcohol or alcoholic beverages during therapy with this drug.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>